Semafore Pharmaceuticals Inc.

Georgetown, IN, United States

Semafore Pharmaceuticals Inc.

Georgetown, IN, United States
SEARCH FILTERS
Time filter
Source Type

Morales G.A.,University of Arizona | Morales G.A.,Semafore Pharmaceuticals Inc. | Garlich J.R.,SignalRx Pharmaceuticals | Garlich J.R.,Semafore Pharmaceuticals Inc. | And 6 more authors.
Journal of Medicinal Chemistry | Year: 2013

Dysregulation of the phosphatidylinositol-3-kinase (PI3K) pathway in a wide range of tumors has made PI3K a consensus target to inhibit as illustrated by more than 15 inhibitors now in clinical trials. Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3K vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials. This inhibitor has properties that impart more in vivo activity than should be warranted by its enzymatic potency, which in general is much lower than other clinical stage PI3K inhibitors. We embarked on the exploration of scaffolds that retained such properties while simultaneously exhibiting an increased potency toward PI3K. This work resulted in the discovery of the 5-morpholino-7H-thieno[3,2-b]pyran-7-one system as the foundation of a new compound class of potential PI3K inhibitors having improved potency toward PI3K. The synthesis and cancer stem cell-based activity of these compounds are reported herein. © 2013 American Chemical Society.

Loading Semafore Pharmaceuticals Inc. collaborators
Loading Semafore Pharmaceuticals Inc. collaborators